Peter Damsbo, MD

Peter Damsbo, MD, from Copenhagen University, has more than 25 years of experience from life science industry and science, including several years in the United States heading up clinical development of diabetes products for Novo Nordisk. Key positions prior to joining Kinexum include Chief Development Officer at Zealand Pharma, Vice President Clinical Drug Development at Novo Nordisk Headquarter, Medical Director Diabetes at Novo Nordisk USA, and Research Fellow at the Steno Diabetes Center focused on research in Type 2 diabetes (more than 20 peer reviewed papers). During his industry career, Peter Damsbo has carried 3 medical projects from preclinical phase through to worldwide registration, including writing the expert reports and presented at meetings and hearings with Health authorities. He has experience in medical device development and conducted numerous drug concept evaluations as well as been involved in drug licensing deals and due diligence processes.   Peter Damsbo has experience in interacting with the health authorities in a number of countries, including most notably FDA and EMEA. He has Attended the Advanced Management Program at INSEAD, Managing Medical Product Innovation at SIMI and Product Business Planning: ‘How do we extract maximum value from our Projects’ by Prof. Ralph Boscheck, IMD   His medical expertise spans over several therapeutic areas, including diabetes, obesity, and metabolic diseases and inflammatory diseases, and includes medical devices across the areas. He is partner in Ventac Partners, a venture catalyst in life science and is associated to the Danish-based KLIFO’s Drug Development Counselling groups.